Metabolic Dysfunction Associated Steatohepatitis clinical trials

Explore recruiting metabolic dysfunction associated steatohepatitis clinical trials.

Recruiting metabolic dysfunction associated steatohepatitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metabolic Dysfunction Associated Steatohepatitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Greece, Germany, Belgium, Netherlands, Poland, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Reducing Non-Alcoholic Steatohepatitis

Czechia

Therapeutic use (Phase IV) EU CTIS Study details

A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Belgium, Greece, Poland, France, Spain, Bulgaria +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Spain, Poland, France, Italy, Bulgaria, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metabolic Dysfunction Associated Steatohepatitis trials by city

Metabolic Dysfunction Associated Steatohepatitis in Toronto Metabolic Dysfunction Associated Steatohepatitis in Vancouver Metabolic Dysfunction Associated Steatohepatitis in Montreal Metabolic Dysfunction Associated Steatohepatitis in Calgary Metabolic Dysfunction Associated Steatohepatitis in Edmonton Metabolic Dysfunction Associated Steatohepatitis in Ottawa Metabolic Dysfunction Associated Steatohepatitis in Winnipeg Metabolic Dysfunction Associated Steatohepatitis in Quebec City Metabolic Dysfunction Associated Steatohepatitis in Hamilton Metabolic Dysfunction Associated Steatohepatitis in Kitchener Metabolic Dysfunction Associated Steatohepatitis in London Metabolic Dysfunction Associated Steatohepatitis in Halifax Metabolic Dysfunction Associated Steatohepatitis in New York Metabolic Dysfunction Associated Steatohepatitis in Los Angeles Metabolic Dysfunction Associated Steatohepatitis in Chicago Metabolic Dysfunction Associated Steatohepatitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease